Olanzapine for the prevention of chemotherapy-induced nausea and vomiting.

Navari, Rudolph M., Qin, Rui, Ruddy, Kathryn J., Liu, Heshan, Powell, Steven F., Bajaj, Madhuri, Dietrich, Leah, Biggs, David, Lafky, Jacqueline M., Loprinzi, Charles L.·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1515725

Cited by (454)

Items 201–300 of 454

A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease
Sheila Lahijani, Maria Adelaida Rueda-Lara, Natalie Susan McAndrew, Ashley M. Nelson, Michelle Guo, Jennifer M. Knight, Lori S. Wiener, Damien M. Miran, Tamryn Fowler Gray, Emma P Keane et al. · 2024 · Transplantation and Cellular Therapy
Unlocking the molecular mechanisms of anticancer and immunomodulatory potentials of cariprazine in triple negative breast cancer
Aleksandar Lazovic, Bojana Simović Marković, Irfan F. Corovic, Tijana Markovic, Marija Andjelkovic, Bojan Stojanović, Ivan Jovanović, Marina M. Mitrović · 2025 · Biomedicine & Pharmacotherapy
Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of randomized controlled trials
Mengyu He, Ruoxin Xu, Miaowen Liu, Yixuan Zhang, Fengming Yi, Yiping Wei, Qing Liu, Wenxiong Zhang · 2021 · Annals of Palliative Medicine
Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
Mototsugu Shimokawa, Naoki Haratake, Kazuki Takada, Gouji Toyokawa, Shinkichi Takamori, Fumitaka Mizuki, Tomoyoshi Takenaka, Toshinobu Hayashi · 2022 · Cancer Management and Research
Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care
Rudolph M. Navari, Kathryn J. Ruddy, Thomas William LeBlanc, Rebecca Anne Clark-Snow, Rita Wickham, G. Binder, Tammy Bratton Coberly, Ravi C. Potluri, Luke M. Schmerold, Eric J. Roeland · 2019 · JCO Oncology Practice
Management of anorexia prevents skeletal muscle wasting during cisplatin‐based chemotherapy for thoracic malignancies
Eriko Miyawaki, Tateaki Naito, Kazuhisa Nakashima, Taichi Miyawaki, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Akira Ono et al. · 2020 · JCSM Clinical Reports
Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
So Rae Lee, Su Min Kim, Min Young Oh, Jae Min Lee · 2020 · Children
The role of pharmacists in multimodal cancer cachexia care
Hironori Fujii, Yunami Yamada, Hirotoshi Iihara, Akio Suzuki · 2023 · Asia-Pacific Journal of Oncology Nursing
Prevention of chemotherapy‐induced vomiting in children receiving multiple‐day cisplatin chemotherapy: A hospital‐based, retrospective cohort study
Kenji Kishimoto, Keiichiro Kawasaki, Atsuro Saito, Aiko Kozaki, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka · 2017 · Pediatric Blood & Cancer
Management of Patients With Chemotherapy-Induced Nausea and Vomiting.
Sally Yowell Barbour · 2017 · Europe PMC (PubMed Central)
Time to re-think the olanzapine dose
Alex Molassiotis · 2019 · The Lancet Oncology
Anti‐cancer therapy made easier: a 25‐year update
Amy Davies, Caroline Lum, Rachel Raju, Evan Ansell, Kate Webber, Eva Segelov · 2020 · Internal Medicine Journal
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy
Hiroko Minatogawa, Naoki Izawa, Takashi Kawaguchi, Tempei Miyaji, Kazuhiro Shimomura, Kazunori Honda, Hirotoshi Iihara, Yasushi Ohno, Yusuke Inada, Hitoshi Arioka et al. · 2020 · BMJ Open
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study
Rony Dev, Linda L. D. Zhong, Abdulrazzak Zarifa, Aya A. Albittar, Laura Rubin, Suyu Liu, Timothy Anthony Yap, Shalini Dalal, David Hui, Daniel D. Karp et al. · 2021 · Investigational New Drugs
Chemotherapy-Associated Nausea and Vomiting
Kelvin Mogesa Manyega, Benjamin Nasara Joseph, Rotkangmwa C. Okunlola, Maxwell Patrick Dapar · 2022 · Annals of African Medicine
A Randomized Clinical Trial Investigating an Integrated Nursing Educational Program to Mitigate Chemotherapy-Induced Nausea and Vomiting in Cancer Patients: The NIV-EC Trial
Cristina Mazzega-Fabbro, Jerry Polesel, Lara Brusutti, Elisa Malnis, Chiara Sirelli, Annalisa Drigo, Marina Manicone, Monica Rizzetto, C. Lisanti, Fabio Puglisi · 2023 · Cancers
Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials
Winnie Yeo, Nicole Ngai, Christopher Yip, Frankie K. F. Mo, Victoria Anna Yeo, Jonathan Ko, Leung Li, Thomas K.H. Lau, Kwai Tung Lai, Elizabeth Pang et al. · 2024 · Cancer Management and Research
Using central gut–brain neuromodulators to manage disorders of gut–brain interaction: a practical guide for gastroenterologists
Matthew Cohen, Asma Fikree, Calum D. Moulton · 2025 · Frontline Gastroenterology
A New Adjuvant Treatment for Glioblastoma Using Aprepitant, Vortioxetine, Roflumilast and Olanzapine: The AVRO Regimen
Richard Eric Kast, Bruno Marques Vieira, Erasmo Barros da Silva · 2025 · International Journal of Molecular Sciences
Chemotherapy-Induced Nausea and Vomiting
MaryAnn B. Wilbur, Michael J. Birrer, David R. Spriggs · 2016 · New England Journal of Medicine
A Case of “Total Nausea:” An Interprofessional Approach to the Management of Chemotherapy-Induced Nausea/Vomiting Complicated by Anxiety and Existential Distress
Neha J. Darrah, Jaime H. Goldberg · 2017 · Journal of Pain and Symptom Management
Patient-related Risk Factors for Nausea and Vomiting With Standard Antiemetics in Patients With Cancer Receiving Carboplatin: A Retrospective Study
Izumi Nasu, Rena Shimano, Hitoshi Kawazoe, Tomonori Nakamura, Yuji Miura, Toshimi Takano, Masahiro Hayashi · 2020 · Clinical Therapeutics
Megestrol acetate dispersible tablets with a 5-HT3 receptor antagonist and dexamethasone vs. 5-HT3 receptor antagonist plus dexamethasone, can better control chemotherapy-induced nausea and vomiting: a randomized controlled study
Yijie Ma, Weijie Zhao, Wenying Deng, Wei Chen, Liangyu Bie, Chi Zhang, Ning Li, Suxia Luo · 2022 · Annals of Translational Medicine
Dexamethasone and Ondansetron Combined Decreases Postoperative Nausea and Vomiting in Orthognathic Surgery Compared With Dexamethasone Alone: A Prospective Randomized Controlled Trial
Yuna Kang, Kyotaro Koshika, Keiko Takashima, Ai Nakakuki, Kazuya Hasunuma, Mayuko Hayashi, Kaori Miyamoto, Maho Yamamoto, Kaori Yoshida, Tatsuya Ichinohe · 2025 · Anesthesia Progress
Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant
Taylor Monson, Devon Greer, Emily Kreikemeier, Susanne Liewer · 2019 · Journal of Oncology Pharmacy Practice
Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial
Akimitsu Maeda, Hiroki Yoshida, Hirotaka Inoue, Masayuki Ejiri, Satoe Yamaguchi, Hideyuki Kushihara, Yoshihiro Yamamoto, Yosuke Ando, Yumiko Sato, Yuusuke Tashiro et al. · 2021 · Annals of Palliative Medicine
OLANZAPINE COMBINED WITH STANDARD ANTIEMETIC REGIMENS FOR PREVENTION OF CHEMOTHERAPY THERAPY-INDUCED NAUSEA AND VOMITING: A SINGLE-CENTER EXPERIENCE FROM SOUTH INDIA
Emmanuel James, P Drisya, Wesley Mannirathil Jose · 2017 · Asian Journal of Pharmaceutical and Clinical Research
Neuroleptic malignant syndrome in patients with cancer: a systematic review
Izumi Sato, Hideki Onishi, Chiaki Kawanishi, Shuhei Yamada, Mayumi Ishida, Koji Kawakami · 2020 · BMJ Supportive & Palliative Care
Toxicidades Gastrointestinais em Mulheres durante Tratamento Quimioterápico do Câncer de Mama
Simone Yuriko Kameo, Bruno Ferreira Amorim, Ricardo Barbosa Lima, Jéssica dos Santos Costa, Glebson Moura Silva, Pabliane Matias Lordelo Marinho, Namiê Okino Sawada · 2021 · Revista Brasileira de Cancerologia
Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study
Takezo Tsutsumi, Shungo Imai, Hitoshi Kashiwagi, Yuki Sato, Mitsuru Sugawara, Yoh Takekuma · 2021 · European Journal of Clinical Pharmacology
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy
Rudolph M. Navari · 2019 · Expert Opinion on Drug Safety
Quality of life comparing carboplatin with cisplatin in the treatment of non–small cell lung cancer
M. Snee · 2018 · European Journal of Cancer
Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
Matti Aapro · 2018 · Supportive Care in Cancer
Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies
Karin Jordan · 2024 · Annals of Oncology
Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea
R. Lee, Minhee Ku, Nam Kyung Je · 2024 · Supportive Care in Cancer
NEPA ( Netupitant/Palonosetron) for the Prevention of Chemotherapy‐Induced Nausea and Vomiting ( CINV ) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial
Rudolph M. Navari, Erminio Bonizzoni · 2025 · Cancer Medicine
Updates in palliative care of patients with gynecologic malignancies in 2026: early integration, resource models, and emerging therapies
Christopher J. Pietras, Teresa Khoo, Daniel Karlin · 2025 · Current Opinion in Obstetrics & Gynecology
Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience
Akihiro Uchiike, Haruka Kono, Katsuhiro Miura, Tatsuya Hayama, Daisuke Tsutsumi, Shinya Tsuboi, Susumu Ohtsuka, Shinji Hidaka · 2023 · Journal of Pharmaceutical Health Care and Sciences
Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study
Hiroe Suzuki‐Chiba, Takaaki Konishi, Shotaro Aso, Kanako Makito, Hiroki Matsui, Taisuke Jo, Kiyohide Fushimi, Hideo Yasunaga · 2024 · International Journal of Clinical Oncology
Optimal Management of Chemotherapy-related Adverse Events
Min Kyu Jung · 2020 · The Korean Journal of Pancreas and Biliary Tract
Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
Yoshitaka Saito, Yoh Takekuma, Takashi Takeshita, Mitsuru Sugawara · 2021 · Scientific Reports
Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic Chemotherapy
Daniel S. Childs, David A. Helfinstine, Lindsey R. Sangaralingham, Jacob J. Orme, Ciara Catherine O'Sullivan, Charles L. Loprinzi, Kathryn J. Ruddy · 2022 · JCO Oncology Practice
Gastrointestinal Side Effects of Anticancer Therapy
José Antonio Uranga, Kulmira Nurgali, Raquel Abalo · 2023 · Springer eBooks
Incorporation of Palliative Care in Gynecologic Oncology
Christianne Persenaire, Daniel Spinosa, Lindsay W. Brubaker, Carolyn Lefkowits · 2023 · Current Oncology Reports
Salsalate and/or metformin therapy confer beneficial metabolic effects in olanzapine treated female mice
Hesham Shamshoum, Kyle D. Medak, Greg L. McKie, Stewart Jeromson, Margaret Hahn, David Charles Wright · 2023 · Biomedicine & Pharmacotherapy
Perspectives in Head and Neck Medical Oncology
Idoroenyi Usua Amanam, Rohan Gupta, Alain C. Mita, Kevin S. Scher, Erminia Massarelli · 2018 · Cancer treatment and research
Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting
Luigi Celio, Chiara Fabbroni · 2018 · Expert Opinion on Pharmacotherapy
The Evaluation of the Effects of N-Acetylcysteine on Cisplatin-Induced Alterations in Exploratory Activity in Elevated Plus Maze Test in Rats
Milica Pantić, Miloš Minić · 2018 · Serbian Journal of Experimental and Clinical Research
Resurgence of Eating Disorders with Olanzapine
Kelly L. Wu, Amanda K. Lorenz, Kelly Christensen, Molly A. Feely, Elise C. Carey, Jacob J. Strand · 2018 · Journal of Palliative Medicine
Medicinal cannabis for chemotherapy‐induced nausea and vomiting: prescribing with limited evidence
Antony J. Mersiades, Martin R. Stockler, Ian Olver, Peter Grimison · 2018 · The Medical Journal of Australia
Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”
Nicola Di Renzo, Lorella Maria Antonia Melillo, Fernando Porretto, Michela Dargenio, Vincenzo Pavone, Domenico Pastore, Patrizio Mazza, Donato Mannina, Anxur Merenda, Nicola Cascavilla et al. · 2019 · Cancer Medicine
Intergenerational comparison of 5-HT3RA in the prevention of chemotherapy-induced nausea and vomiting in gastric cancer patients receiving cisplatin-based chemotherapy: an observational study using a Japanese administrative claims database
Yuji Kunitomi, Masayuki Nakashima, Tomotsugu Seki, Kazuki Ide, Koji Kawakami · 2021 · Supportive Care in Cancer
Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi · 2022 · Journal of Pharmaceutical Health Care and Sciences
Olanzapine enhances the effect of conventional drugs in chemotherapy inducing nausea and vomiting: A randomized clinical trial.
Atefe Khani, Ali Eishy Oskuyi, Rahim Asghari, Hamid Reza Khalkhli, Hamdollah Sharifi · 2022 · PubMed Central
AFSOS-SFRO-SFH-SFNEP-SFCE-GFRP guidelines on radio-induced nausea and vomiting
J.-C. Faivre, F Tomaszewski, Charlotte Demoor-Goldschmitt, Arnaud Beddok, A. Malgras, A. Schmitt, Joseph Fabre, Aurore Perrot, Nicolas Jovenin, Julia Salleron et al. · 2022 · Critical Reviews in Oncology/Hematology
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)
Hitomi Sakai, Junji Tsurutani, Yukinori Ozaki, Hiroshi Ishiguro, Kazuki Nozawa, Kenichi Watanabe, Shigeto Maeda, Takamichi Yokoe, Chiyo K. Imamura, Koji Matsumoto et al. · 2023 · BMJ Open
Repositioning of Antipsychotic Phenothiazines for Cancer Therapy: Nanotechnological Opportunities to Overcome Obstacles
Tiago Rodrigues · 2023 · Current Pharmaceutical Design
Malignant Phyllodes Tumors: Diagnostic, Investigative and Therapeutic Challenges
Shuhei Suzuki, Manabu Seino, Hidenori Sato, Masaaki Kawai, Yosuke Saito, Koki Saito, Yuta Yamada, Koshi Takahashi, Ryosuke Kumanishi, Tadahisa Fukui · 2025 · Encyclopedia
Portuguese consensus on the prevention and treatment of nausea and vomiting induced by cancer treatments
Cláudia Vieira, Rui Bergantim, Elsa Madureira, Juan Carlos Mellídez Barroso, Miguel Labareda, Sara T. Parreira, Ana Castro, Ana Macedo, Sandra Custódio · 2023 · Porto Biomedical Journal
Strategies to enhance management of HER2-positive breast cancer in the elderly: an expert consensus perspective
Sonia Del Barco, Almudena Cotes, Mercedes Cavanagh, Regina Gironés Sarrió, Borja Lopez De San Vicente, Elena Galve-Calvo, Sònia Servitja · 2025 · Clinical & Translational Oncology
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience
Luana Guimarães de Sousa, James E. Bates, Payal Anand, Jimmy J. Caudell, Alexander Dimitrios Colevas, Christina L. Runge, Jeffrey D. Sharon, Musaddiq J. Awan, Beth Michelle Beadle, Jennifer Hsing Choe et al. · 2025 · JNCI Journal of the National Cancer Institute
The Role of New Agents and Supportive Care in a Multimodal Approach to Cancer Cachexia
Egidio Del Fabbro, Sudeep Pandey · 2026 · Cancers
Antiemetic medication efficacy during EPOCH and R-EPOCH treatment
Megan Fleming, Allison Carr, Junan Li, Jordan Lundberg, Kerry Anne Rogers · 2020 · Journal of Oncology Pharmacy Practice
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)
Rudolph M. Navari, Jennifer G. Le‐Rademacher, Fabrice Smieliauskas, Kathryn J. Ruddy, Thomas James Saphner, Heshan Liu, Elizabeth Harlos, Adedayo A. Onitilo, Karthik V. Giridhar, Preet Paul Singh et al. · 2023 · The Oncologist
Addition of thalidomide for prevention of chemotherapy-induced nausea and vomiting in the second cycle after the failure of four-drug regimen in the first cycle
Nishil Gowda, Mirunalini Ravichandran, Jeyaselvi Indrajithu, Tamizharasan Paninathan, Biswajit Dubashi, Smita Kayal, Prasanth Ganesan · 2025 · Medical Oncology
A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy
Tsutomu Takahashi, Takahiro Okada, Fumiyoshi Ikejiri, Shunsuke Ito, Yusuke Okada, Fumimasa Takahashi, Satoshi Kumanomido, Yumi Jo, Koji Adachi, Chie Onishi et al. · 2017 · International Journal of Clinical Oncology
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis
Senri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, Hitoshi Kawazoe, Kazuki Tanaka, Yukiyoshi Fujita, Masakazu Abé, Hisao Imai, Masato Karayama, Yoh Hayasaki et al. · 2022 · BMC Cancer
Nanobiotechnology-based strategies in alleviation of chemotherapy-mediated cardiotoxicity
Xuanming Luo · 2023 · Environmental Research
Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study
Shiori Sadaka, Hirotoshi Iihara, Koichi Ohata, Serika Matsuoka, Daichi Watanabe, Takuji Iwashita, Shinya Uemura, Masahito Shimizu, Akio Suzuki · 2023 · Supportive Care in Cancer
Randomized Placebo-Controlled Trial of Topical Capsaicin for Delayed Chemotherapy-Induced Nausea and Vomiting
Heber Rew Bright, Ashish Singh, Anjana Joel, Josh Thomas Georgy, Ajoy Oommen John, Pradeep Rajkumar, Hema Jiji, Lisa Stehno‐Bittel, Prasanna Samuel, Sujith John Chandy · 2024 · JCO Global Oncology
Psychiatric Implications and Treatments for Patients Undergoing Treatment of Breast Cancer
Robin Valpey, Elizabeth Hale, Isabella Maria Friederike Kratzer · 2025 · Advances in Psychiatry and Behavioral Health
Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting
Bernardo Leon Rapoport, Pere Gascón, Florian Scotté, Karin Jordan, Massimo Di Maïo, Sussanne Börjeson, Sam Hjelmeland Ahmedzai · 2017 · European Oncology & Haematology
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial
Hirotoshi Iihara, Mototsugu Shimokawa, Takenobu Gomyo, Yukiyoshi Fujita, Tsutomu Yoshida, Norihiko Funaguchi, Koichi Minato, Daizo Kaito, Tomohiro Osawa, Momoko Yamada et al. · 2019 · BMJ Open
A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies
Bo‐Ya Xiao, Tong Su, Yujia Huang, Guo‐He Lin, Zhao-Bo Liu, Yunxiang Tang, Bi‐Cheng Wang · 2021 · Supportive Care in Cancer
The Efficacy and Safety of Adding Olanzapine to Triple Drugs Regimen to Prevent Chemotherapy-induced Nausea and Vomiting: A systematic Review and Meta-analysis of RCTs
Sharanabasayyaswamy B. Hiremath, Srinivas L. Devendrappa · 2022 · Pharmacology and Clinical Pharmacy Research
A possible role for ghrelinergic stimulation through blockade of 5-HT2B/5-HT2C receptors in antiemetic action of olanzapine
Itoh Y · 2019 · Journal of Translational Science
Sample size re‐estimation for covariate‐adaptive randomized clinical trials
Xin Li, Wei Ma, Feifang Hu · 2021 · Statistics in Medicine
[Prevention using cephalothin in open-heart surgery].
Peter Eigel, A. Tschirkov, H Knothe, Eike Tobias Krause, PETER SATTER · 1977 · PubMed
Management of Pregnancy Associated Breast Cancer: a Review
Stephanie Ng, Kristina Shaffer, Trishala Meghal, Lilian Thomas-Harris, Yusra B. Medik, Chirag Shah · 2022 · Current Breast Cancer Reports
Olanzapine for The Prevention of Nausea and Vomiting Caused by Chemoradiotherapy with High-Dose Cisplatin for Head and Neck Cancer
Satoshi Koyama, Hiroaki Ehara, Ryohei Donishi, Tsuyoshi Morisaki, Kenkichiro Taira, Takahiro Fukuhara, Kazunori Fujiwara · 2023 · Yonago acta medica
Symptoms in Advanced Hematologic Malignancies and Other Serious Hematologic Conditions
Mellar P. Davis, Carlos Fernandez, Nicki Vithalani, Lauren Elizabeth Nicholls, Glen Digwood · 2023 · Springer eBooks
Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial
Hirotoshi Iihara, Masamichi Iwai, Ryo Morita, Yukiyoshi Fujita, Keiko Ohgino, Takuma Ishihara, Chiemi Hirose, Yasuyuki Suzuki, Ken Masubuchi, Hitoshi Kawazoe et al. · 2024 · Lung Cancer
The evolving landscape of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: inspiration from cisplatin-based antiemetic and non-antiemetic trials
Ya Sun, Yalan Wang, Gang Chen, Yaxiong Zhang, Li Zhang, Xi Chen · 2024 · Supportive Care in Cancer
Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India
Sneh Bhargave, Atul Sharma, Babita Kataria, Atul Batra, Deepam Pushpam, Aparna Sharma, Raja Pramanik, Prabhat Singh Malik, Ranjit Kumar Sahoo, Sachin Khurana et al. · 2025 · JCO Global Oncology
Comparative Study of Efficacy and Safety of Olanzapine as Add-on Therapy to Conventional Regimen in Preventing Chemotherapy-induced Nausea and Vomiting
Krishna Sai Attili, H Bura, Vineela Ganta, Sweta Bindu Mendu, Usha Kiran Prayaga · 2025 · SSR Institute of International Journal of Life Sciences
Low Dose Olanzapine for Cases of Refractory Nausea and Vomiting and Vertigo After Cerebellar Stroke
Eric Lewin Altschuler, Adrien Golocovsky, James Guider, Isaac Kim, Ivani Proaño, Manuela Morales-Rodriguez, Neil N. Jasey, Radhika K. Bapineedu · 2025 · Journal of Pain and Symptom Management
Development and validation of predictive model for emesis in cervical cancer patients receiving concurrent chemoradiotherapy based on multi-institutional retrospective study
Kensuke Yoshida, Hajime Morita, Masaki Nakai, Yusuke Kawamura, Takuma Matsumoto, Yoshinobu Gohara, Naoto Hoshino, Naoya Tonomura, Manami Banba, Ayako Yamaguchi et al. · 2025 · Scientific Reports
New therapies to treat nausea and vomiting: clinical need, progress towards novelty and research challenges
Gareth John Sanger, John Foster Golding, Paul L. R. Andrews · 2026 · Expert Review of Clinical Pharmacology
Nausea and Vomiting
John Daniel Hainsworth · 2020 · Elsevier eBooks
Dexamethasone-free antiemetic strategy for highly emetogenic chemotherapy: safety and efficacy-pilot study
Atul Sharma, Akash Kumar, Annie Kanchan Baa, Sudhir Kirar, Atul Sharma, Sameer Bakhshi, Ajay Gogia, Prabhat Singh Malik, Sameer Rastogi, Atul Batra et al. · 2023 · BMJ Supportive & Palliative Care
Olanzapine within steroid-sparing antiemetic regimen to prevent chemotherapy-induced nausea and vomiting in patients with acute leukemia receiving multi-day intensive chemotherapy
Grace Hsu, Ciera L. Patzke, Justin Lawson, Vu H. Duong, Ashkan Emadi, Sandrine Niyongere, Alison P. Duffy · 2023 · Journal of Oncology Pharmacy Practice
Chinese expert consensus on prevention and treatment of delayed nausea and vomiting (2022 Edition)
Xianglin Yuan · 2023 · Oncology and Translational Medicine
Pharmacological Strategies for Postdischarge Nausea and Vomiting: Evidence-based Review Update
Tito D Tubog, Terri D Kane · 2024 · Journal of PeriAnesthesia Nursing
Efficacy of triplet antiemetic prophylaxis against chemotherapy-induced nausea and vomiting in patients with soft tissue sarcomas receiving consecutive-day doxorubicin and ifosfamide therapy
Yunami Yamada, Hirotoshi Iihara, Akihito Nagano, Hironori Fujii, Masanori Tsugita, Ryo Hoshino, Koki Hara, Ryo Kobayashi, Haruhiko Akiyama, Akio Suzuki · 2025 · Supportive Care in Cancer
Treatment of nausea with innovative antiemetics
Yuki Fujii, Hanae Ida, Tatsushi Shimokuni, Fumihiko Haraguchi · 2017 · Expert Review of Quality of Life in Cancer Care
Efficacy of Single-dose First-generation 5-HT3 Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy
Daizo Kaito, Hirotoshi Iihara, Norihiko Funaguchi, Junki Endo, Fumitaka Ito, Komei Yanase, Sayaka Toyoshi, Yuka Sasaki, Chiemi Hirose, NATSUMI ARAI et al. · 2017 · Anticancer Research
OLANZAPINE FOR THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
А. А. Rumyantsev, Илья Анатольевич Покатаев, M. Yu. Fedyanin, A. S. Tjulandina, Alexey Alexandrovich Tryakin, Sergey A. Tjulandin · 2018 · Malignant tumours
The prevention and treatment of chemotherapy-induced nausea and vomiting in children and adolescents receiving cancer treatment: the current status and possibilities for improvement
Nikolay V. Zhukov, L. L. Kazakova, Galina A. Novichkova · 2020 · Pediatric Hematology/Oncology and Immunopathology
Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients
Junichi Hara, Yoshiyuki Kosaka, Katsuyoshi Koh, Kimikazu Matsumoto, Tadashi Kumamoto, Hiroyuki Fujisaki, Yuji Ishida, Ryoko Suzuki, Shinji Mochizuki, Hiroaki Goto et al. · 2021 · Japanese Journal of Clinical Oncology
Management of Intractable Symptoms in Oncologic Care
Katie L. Dziedzic, Ross H. Albert · 2021 · Current Oncology Reports